Global(EN)
WHO Meeting Held to Review the Results of Sinovac SARS Vaccine Phase I Trial and Discuss Phase II Protocols
Geneva -- On June 1 2005 the Initiative for Vaccine Research (IVR), a division of World Health Organization (WHO), organized a conference to review the results of the Phase I SARS vaccine trial and discuss Phase II protocol at WHO headquarters in Geneva . Dr. Marie-Paule Kieny Director of IVR hosted the meeting, which was attended by seven WHO professionals, and representatives from the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) and Sinovac Biotech Ltd. The NICPBP representatives included Mr. Guanmu Dong, director of NIBPCP, and Mr. Junzhi Wang, deputy general director of NICPBP. Representatives from Sinovac were Ms. Nan Wang, vice president of Sinovac, and Dr. Hong Gao, medical manager of Sinovac.
Dr.Gao gave a presentation about the Phase I clinical trial results of Sinovac’s SARS vaccine, and a draft proposal for conduction Phase II clinical trials. After detailed discussions, the WHO representatives expressed to the general audience, their satisfaction with the results of the phase I trial. The second topic of discussion was on the protocol of Phase II trial. The WHO professionals gave several valuable technical recommendations on Phase II trial.
http://www.nicpbp.org.cn/SHW/nicpbp.nsf/sydocs/E0C8E95D1F7E317F4825701B001408C8?opendocument
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
